Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.48
BABY's Cash-to-Debt is ranked lower than
71% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. BABY: 0.48 )
Ranked among companies with meaningful Cash-to-Debt only.
BABY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 43.6 Max: No Debt
Current: 0.48
0.32
No Debt
Equity-to-Asset 0.63
BABY's Equity-to-Asset is ranked lower than
53% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. BABY: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
BABY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.79  Med: 0.82 Max: 0.94
Current: 0.63
-1.79
0.94
Debt-to-Equity 0.28
BABY's Debt-to-Equity is ranked lower than
55% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. BABY: 0.28 )
Ranked among companies with meaningful Debt-to-Equity only.
BABY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.1  Med: 0.05 Max: 0.37
Current: 0.28
-0.1
0.37
Debt-to-EBITDA 3.78
BABY's Debt-to-EBITDA is ranked lower than
72% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. BABY: 3.78 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BABY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03  Med: 1.34 Max: 16.94
Current: 3.78
0.03
16.94
Interest Coverage 1.39
BABY's Interest Coverage is ranked lower than
96% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. BABY: 1.39 )
Ranked among companies with meaningful Interest Coverage only.
BABY' s Interest Coverage Range Over the Past 10 Years
Min: 1.39  Med: 68.15 Max: 158.01
Current: 1.39
1.39
158.01
Piotroski F-Score: 4
Altman Z-Score: 3.82
Beneish M-Score: -2.60
WACC vs ROIC
6.95%
3.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 1.88
BABY's Operating Margin % is ranked higher than
50% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. BABY: 1.88 )
Ranked among companies with meaningful Operating Margin % only.
BABY' s Operating Margin % Range Over the Past 10 Years
Min: 1.75  Med: 10.34 Max: 15.75
Current: 1.88
1.75
15.75
Net Margin % -3.53
BABY's Net Margin % is ranked lower than
57% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. BABY: -3.53 )
Ranked among companies with meaningful Net Margin % only.
BABY' s Net Margin % Range Over the Past 10 Years
Min: -4.8  Med: 6.79 Max: 11.15
Current: -3.53
-4.8
11.15
ROE % -4.42
BABY's ROE % is ranked lower than
57% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. BABY: -4.42 )
Ranked among companies with meaningful ROE % only.
BABY' s ROE % Range Over the Past 10 Years
Min: -4.83  Med: 6.43 Max: 10.54
Current: -4.42
-4.83
10.54
ROA % -2.69
BABY's ROA % is ranked lower than
55% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. BABY: -2.69 )
Ranked among companies with meaningful ROA % only.
BABY' s ROA % Range Over the Past 10 Years
Min: -3.46  Med: 4.89 Max: 8.3
Current: -2.69
-3.46
8.3
ROC (Joel Greenblatt) % -2.97
BABY's ROC (Joel Greenblatt) % is ranked higher than
55% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. BABY: -2.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BABY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.53  Med: 30.98 Max: 56.94
Current: -2.97
-12.53
56.94
3-Year Revenue Growth Rate 12.10
BABY's 3-Year Revenue Growth Rate is ranked higher than
72% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. BABY: 12.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BABY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.9  Med: 11 Max: 38.3
Current: 12.1
-61.9
38.3
3-Year EBITDA Growth Rate -11.50
BABY's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. BABY: -11.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BABY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.4 Max: 863.2
Current: -11.5
0
863.2
GuruFocus has detected 1 Warning Sign with Natus Medical Inc BABY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BABY's 30-Y Financials

Financials (Next Earnings Date: 2019-02-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

BABY Guru Trades in Q3 2017

Chuck Royce 251 sh (New)
Ken Fisher 589,234 sh (+0.16%)
Jim Simons Sold Out
Steven Cohen Sold Out
Robert Olstein 86,200 sh (-0.74%)
Diamond Hill Capital 528,624 sh (-3.03%)
Mariko Gordon 1,385,533 sh (-5.80%)
Columbia Wanger 1,171,097 sh (-31.01%)
» More
Q4 2017

BABY Guru Trades in Q4 2017

Jim Simons 176,245 sh (New)
HOTCHKIS & WILEY 9,703 sh (New)
Ken Fisher 584,829 sh (-0.75%)
Chuck Royce 248 sh (-1.20%)
Columbia Wanger 1,149,442 sh (-1.85%)
Diamond Hill Capital 510,364 sh (-3.45%)
Mariko Gordon 1,295,637 sh (-6.49%)
Robert Olstein 37,850 sh (-56.09%)
» More
Q1 2018

BABY Guru Trades in Q1 2018

Robert Olstein 66,030 sh (+74.45%)
Chuck Royce 294 sh (+18.55%)
HOTCHKIS & WILEY 9,994 sh (+3.00%)
Mariko Gordon Sold Out
Diamond Hill Capital 509,954 sh (-0.08%)
Ken Fisher 574,935 sh (-1.69%)
Jim Simons 165,945 sh (-5.84%)
» More
Q2 2018

BABY Guru Trades in Q2 2018

Chuck Royce 466 sh (+58.50%)
HOTCHKIS & WILEY Sold Out
Ken Fisher 574,375 sh (-0.10%)
Diamond Hill Capital 508,227 sh (-0.34%)
Robert Olstein 35,850 sh (-45.71%)
Jim Simons 67,345 sh (-59.42%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:TSE:6960, XTER:SBS, NAS:OFIX, SZSE:300326, NAS:XENT, SHSE:600587, SZSE:300273, SZSE:300642, XTER:DRW3, TSE:4548, HKSE:01302, TSE:4549, NAS:KTWO, NAS:MDXG, TSE:7817, NAS:AXGN, NYSE:CRY, SZSE:000607, XPAR:GBT, XTAE:MZOR » details
Traded in other countries:NM4.Germany,
Headquarter Location:USA
Natus Medical Inc provides newborn care, neurology healthcare products and services used for screening, diagnosis, detection, treatment, monitoring and tracking of medical ailments in newborn care, epilepsy, and balance and mobility disorders.

Natus Medical Inc provides healthcare products related to newborn care and neurology. Its products are used to diagnose and treat newborn medical conditions, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and mobility disorders. The firm operates in two business units: neurology and newborn care. The neurology business generates the majority of revenue and includes products and services for diagnostic electroencephalography, intensive care unit monitoring, electromyography, and sleep analysis. The newborn care business sells products and services for newborn care, such as hearing screening, brain injury, thermoregulation, and jaundice management products. Natus Medical receives the majority of its revenue from sales in the United States.

Ratios

vs
industry
vs
history
Forward PE Ratio 16.81
BABY's Forward PE Ratio is ranked higher than
73% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. BABY: 16.81 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.52
BABY's PB Ratio is ranked higher than
59% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. BABY: 2.52 )
Ranked among companies with meaningful PB Ratio only.
BABY' s PB Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.44 Max: 4.26
Current: 2.52
0.79
4.26
PS Ratio 1.99
BABY's PS Ratio is ranked higher than
64% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. BABY: 1.99 )
Ranked among companies with meaningful PS Ratio only.
BABY' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.31 Max: 4.42
Current: 1.99
0.95
4.42
Price-to-Free-Cash-Flow 59.58
BABY's Price-to-Free-Cash-Flow is ranked lower than
85% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. BABY: 59.58 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BABY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.63  Med: 29.37 Max: 159.78
Current: 59.58
12.63
159.78
Price-to-Operating-Cash-Flow 42.31
BABY's Price-to-Operating-Cash-Flow is ranked lower than
86% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. BABY: 42.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BABY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.19  Med: 24.52 Max: 75.49
Current: 42.31
10.19
75.49
EV-to-EBIT -244.68
BABY's EV-to-EBIT is ranked lower than
94% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. BABY: -244.68 )
Ranked among companies with meaningful EV-to-EBIT only.
BABY' s EV-to-EBIT Range Over the Past 10 Years
Min: -277.9  Med: 22.9 Max: 197.6
Current: -244.68
-277.9
197.6
EV-to-EBITDA 36.96
BABY's EV-to-EBITDA is ranked lower than
74% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. BABY: 36.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
BABY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.2  Med: 16.95 Max: 5653.1
Current: 36.96
-82.2
5653.1
EV-to-Revenue 2.16
BABY's EV-to-Revenue is ranked higher than
65% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. BABY: 2.16 )
Ranked among companies with meaningful EV-to-Revenue only.
BABY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 2.3 Max: 4.4
Current: 2.16
0.8
4.4
Shiller PE Ratio 71.48
BABY's Shiller PE Ratio is ranked lower than
64% of the 58 Companies
in the Global Medical Devices industry.

( Industry Median: 49.95 vs. BABY: 71.48 )
Ranked among companies with meaningful Shiller PE Ratio only.
BABY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 43.71  Med: 75.38 Max: 115
Current: 71.48
43.71
115
Current Ratio 2.62
BABY's Current Ratio is ranked higher than
58% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. BABY: 2.62 )
Ranked among companies with meaningful Current Ratio only.
BABY' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 3.26 Max: 16.01
Current: 2.62
1.3
16.01
Quick Ratio 1.89
BABY's Quick Ratio is ranked higher than
58% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. BABY: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
BABY' s Quick Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.54 Max: 15.09
Current: 1.89
0.91
15.09
Days Inventory 121.74
BABY's Days Inventory is ranked higher than
65% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. BABY: 121.74 )
Ranked among companies with meaningful Days Inventory only.
BABY' s Days Inventory Range Over the Past 10 Years
Min: 100.58  Med: 115.47 Max: 132.84
Current: 121.74
100.58
132.84
Days Sales Outstanding 84.79
BABY's Days Sales Outstanding is ranked lower than
72% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. BABY: 84.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
BABY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.74  Med: 89.32 Max: 112.34
Current: 84.79
81.74
112.34
Days Payable 33.64
BABY's Days Payable is ranked lower than
66% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. BABY: 33.64 )
Ranked among companies with meaningful Days Payable only.
BABY' s Days Payable Range Over the Past 10 Years
Min: 33.64  Med: 58.58 Max: 92.09
Current: 33.64
33.64
92.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
BABY's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. BABY: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BABY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -185.4  Med: -3.3 Max: -0.5
Current: -0.5
-185.4
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 24.53
BABY's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 7.79 vs. BABY: 24.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BABY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.09  Med: 7.01 Max: 2050
Current: 24.53
1.09
2050
Price-to-Tangible-Book 11.50
BABY's Price-to-Tangible-Book is ranked lower than
84% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. BABY: 11.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BABY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.02  Med: 5.26 Max: 64.5
Current: 11.5
1.02
64.5
Price-to-Intrinsic-Value-Projected-FCF 1.63
BABY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. BABY: 1.63 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BABY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.81  Med: 1.73 Max: 8.51
Current: 1.63
0.81
8.51
Price-to-Median-PS-Value 0.86
BABY's Price-to-Median-PS-Value is ranked higher than
66% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. BABY: 0.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BABY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.1 Max: 3.15
Current: 0.86
0.14
3.15
Earnings Yield (Greenblatt) % -0.43
BABY's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. BABY: -0.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BABY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6.2  Med: 4 Max: 19
Current: -0.43
-6.2
19
Forward Rate of Return (Yacktman) % -2.54
BABY's Forward Rate of Return (Yacktman) % is ranked higher than
73% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. BABY: -2.54 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BABY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.2  Med: 3.85 Max: 22.9
Current: -2.54
-3.2
22.9

More Statistics

Revenue (TTM) (Mil) $521.34
EPS (TTM) $ -0.56
Beta0.92
Volatility31.23%
52-Week Range $27.69 - 41.55
Shares Outstanding (Mil)33.78

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 527 553 582
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.07 0.93 1.45
EPS without NRI ($) -0.07 0.93 1.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}